Revive talks DRDC study on bucillamine for nerve agents

Executive Summary

• Revive Therapeutics provided an update on its collaborative research study with Defence R&D Canada (DRDC) evaluating bucillamine as a potential treatment for nerve agent exposure.
• The study is currently in progress, and the company is awaiting final findings, which will be released only with DRDC's express authorization.
• Revive confirmed it will continue to provide updates as the study advances toward completion.

Key Details

• Study Subject: Evaluation of bucillamine as a potential treatment for nerve agent exposure.
• Collaborator: Defence R&D Canada -- Suffield Research Centre (DRDC), an agency within the Canadian Department of National Defence.
• Study Status: The research study remains in progress.
• Data Release: Final findings are pending and will be released only with the express authorization of DRDC.
• Company Focus: Revive Therapeutics is a life sciences company focused on infectious diseases and medical countermeasures, leveraging FDA regulatory incentives (emergency use authorization, orphan drug, fast-track, and breakthrough therapy designations).
• Other Programs: The company is also exploring bucillamine for long COVID and advancing psilocybin and molecular hydrogen therapeutics.

Notable Quotes

• "The research study evaluating bucillamine remains in progress, and the company is awaiting the final findings, which will be released only with the express authorization of DRDC."